Treatment of Intermediate Risk DTC Patients

Contemporary Management of Recurrent Nodal Disease in Differentiated Thyroid Carcinoma

Shorook Na’ara, Moran Amit, Eran Fridman, and Ziv Gil


Differentiated thyroid carcinoma (DTC) comprises over 90% of thyroid tumors and includes papillary and follicular carcinomas. Patients with DTC have an excellent prognosis, with a 10-year survival rate of over 90%. However, the risk of recurrent tumor ranges between 5% and 30% within 10 years of the initial diagnosis. Cervical lymph node disease accounts for the majority of recurrences and in most cases is detected during follow-up by ultrasound or elevated levels of serum thyroglobulin. Recurrent disease is accompanied by increased morbidity. The mainstay of treatment of nodal recurrence is surgical management. We provide an overview of the literature addressing surgical management of recurrent or persistent lymph node disease in patients with DTC.

Rambam Maimonides Med J 2016;7(1):e0006